EGFR and glioblastoma: Molecular profiling showed that the overwhelming majority of histologically lower CNS WHO grade 2 and grade 3 diffuse astrocytomas exhibiting the IDH-wt status, shared signature in genomic alterations (either EGFR amplification, or concurrent +7/—10, or TERT promoter mutation) and clinical outcomes with the former primary GBM, WHO grade IV or currently classified GBM, CNS WHO grade 4, suggesting those tumors were only under-represented GBMs [72].